Home > Investors
2017 News and Events
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
03/17/17The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
—Inclisiran demonstrated significant and sustained reductions in LDL-C and high standards of safety and tolerability— —Optimal starting dose regimen (300 mg injection administered on Day-1 and Day-90) lowered LDL-C by average of 52.6% (64 mg/dL) and up to 81% (122 mg/dL) at Day-180, and by time-adjusted mean of >50% (63 mg/dL) for the six-month period from Day-90 through Day-270; every patient displayed significant response and mean LDL-C redu... 
Printer Friendly Version
03/14/17The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
Late-breaking session featuring data from ORION-1 study to be webcast simultaneously with presentation at 1:30 p.m. on March 17, 2017 New Time for Conference Call – Previously-scheduled conference call/webcast to review data from ORION-1 moved to 4:30 p.m. on March 17, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 14, 2017-- The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneousl... 
Printer Friendly Version
03/06/17The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions
– Late-breaking data from ORION-1 Phase II study of inclisiran (PCSK9si) will be reviewed by the Company and members of its distinguished advisory board – PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis inhibitor. D... 
Printer Friendly Version
02/28/17The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 28, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its financial results for the fourth-quarter and full-year ended December 31, 2016. “Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We announced positive top-line results from the ORION-1 Phas... 
Printer Friendly Version
02/21/17The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s new drug application (NDA) filing for Carbavance® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTIs). The FDA does not currently plan to hold an advisory committee meeting to discuss the application. ... 
Printer Friendly Version
02/17/17The Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February 28, 2017
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 17, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Tuesday, February 28, 2017, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2016 financial results and operational developments. The dial-in information to access the call is listed below: U.S./Canada: (877) 359-9508 International: (224) 357-2393 Conference ID: 66296847 A taped r... 
Printer Friendly Version
01/25/17The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 25, 2017-- The Medicines Company (Nasdaq: MDCO) today announced that full safety and efficacy data from the ORION-1 Phase 2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the American College of Cardiology's 66th Annual Scientific Session (ACC.17), to be held March 17-19, 2017, in Washington D.C. The ORION-1 study will be presented in the “Late-Breaking Cl... 
Printer Friendly Version
01/08/17The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Compelling safety and efficacy data from Day 180 interim analysis Inclisiran continued to demonstrate significant and durable LDL-C reduction, reaffirming the potential for a highly-differentiated dosing regimen of two or three injections per year Inclisiran continued to demonstrate high standards of safety and tolerability The Medicines Company reinforces its commitment to advancing the development of inclisiran with initi... 
Printer Friendly Version
01/04/17The Medicines Company to Present at J. P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 4, 2017-- The Medicines Company (Nasdaq: MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, at 7:30 a.m., Pacific time. A live audio webcast of the presentation will be available in the “Investors” section of The Medicines Company website, www.themedicinescompany.com, ... 
Printer Friendly Version